Skip to Content
  • Contact us
  • International Headquarters
  • Adverse reactions - Pharmacovigilance
  • Grifols Ethics Line
  • Change Language
  • Español
  • Deutsch
  • 中文
'Grifols.com' logo 'Grifols.com' logo

  • Company

    Since 1909, Grifols has worked to improve the health and well-being of people around the world.

    Read more

    • Corporate Structure

      • Board of Directors
      • Management Team
    • What We Do 
      • Biopharma
      • Diagnostic
      • Bio Supplies
      • Healthcare Solutions for Hospitals
    • Mission, vision and values 
    • Ethics and Compliance 
    • Our History 
    • Grifols Museum 
      • La Casa: Where It All Began
      • The Plant: People Helping People
      • The World: From Family Business to Global Company
    • Grifology 
      • The Cabinet
    • Grifols Engineering 
    Every action we take is motivated by our mission to improve people's lives. 
    Our unique and remarkable history combines scientific expertise with a desire to serve patients and society. 
    We develop, produce and market innovative medicines, solutions and services in more than 110 countries. 

  • Innovation

    Grifols is full speed ahead on developing the next innovative breakthroughs across multiple therapeutic areas.  

    Read more
    • Plasma Powerhouse 
    • Beyond Plasma 
    • Key Therapeutic Areas 
      • Immunology
      • Hepatology and Intensive Care
      • Pulmonology
      • Hematology
      • Neurology
      • Infectious Diseases
      • Further Therapeutic Opportunities
    • CHRONOS-PD: Plasma Science in Parkinson’s Research 
    • Extending Our Innovative Reach 
      • Team Up with Grifols Innovation and New Technologies
      • Scientific Awards and Programs
    • Connecting Knowledge - Our R&D Network 
    • International Plasma Awareness Week 
    We apply our growing knowledge of plasma to change healthcare. 
    Our treatments are enhancing people’s well-being and quality of life. 
    We’re drawing on a broad scientific base to continue innovating. 

  • Sustainability

    Grifols' longstanding commitment to people and the planet entails helping society on all fronts.

    Read more

    • Social Commitment

      • Supporting Patients
      • Supporting Donors
      • Our People
      • Social Action
    • Environmental Responsibility 
    • Ethical Leadership 
    • Sustainability Reports & Corporate Policies 
    2025 Integrated and Sustainability Annual Report 
    Innovating with purpose to drive positive impact 
  • Products

  • Investors

    Read more

    • Stock Information

      • Stock and share capital
      • Dividends
      • Major Holders and Treasury Stock
      • Agreements between Shareholders
      • Analyst Coverage

    • Financials

      • Financial Results
      • Annual Accounts
      • Fixed Income and Credit Ratings
      • Average Period of Payment to Suppliers
      • Key Figures
    • Press Releases 
    • Presentations and Events 
    • Agenda 

    • Communications with CNMV and SEC

      • CNMV
      • SEC
      • Other Relevant Information
      • Inside Information
      • Significant events until 8 February 2020
    • Corporate Stewardship Reports 

    • Corporate Governance

      • Board of Directors
      • General Shareholders’ Meeting
      • Annual Corporate Governance Report
      • Directors' Remuneration Report
      • Articles of Association
      • Corporate Policies
    • Mergers 
    • Biotest: Voluntary Takeover Offer | Freiwilliges Übernahmeangebot (2021) 
    • Biotest: Acquisition offer (delisting) / freiwilliges Erwerbsangebot (Delisting) (2025) 
    Presentation First-Half 2026 Results 
    2025 Integrated and Sustainability Annual Report 

  • Careers

    People are at the heart of our business. We are committed to continued investment in training and development.

    Explore Opportunities
    • Why Grifols 
      • People & Culture
      • Our teams
    • Training and Development 
    • Hiring Journey 
    • Early Careers 

  • Media

    Latest news about the company and contact information for journalists and communication professionals.

    Read more
    • Newsroom 
    • Events 
      • H1 2026 Financial Results
      • General Shareholders' Meeting 2026
    • Media Contacts 
    • Media Center 

  • Suppliers

    At Grifols, we believe in long-term, mutually trusting relationships with our partners.

    More details
    • Join Grifols Supplier Network 
  • Change Language
  • Español
  • Deutsch
  • 中文
  • Company
    • Company
    • Corporate Structure
      • Board of Directors
      • Management Team
    • What We Do
      • What We Do
      • Biopharma
      • Diagnostic
      • Bio Supplies
      • Healthcare Solutions for Hospitals
    • Mission, vision and values
    • Ethics and Compliance
    • Our History
    • Grifols Museum
      • Grifols Museum
      • La Casa: Where It All Began
      • The Plant: People Helping People
      • The World: From Family Business to Global Company
    • Grifology
      • Grifology
      • The Cabinet
    • Grifols Engineering
  • Innovation
    • Innovation
    • Plasma Powerhouse
    • Beyond Plasma
    • Key Therapeutic Areas
      • Key Therapeutic Areas
      • Immunology
      • Hepatology and Intensive Care
      • Pulmonology
      • Hematology
      • Neurology
      • Infectious Diseases
      • Further Therapeutic Opportunities
    • CHRONOS-PD: Plasma Science in Parkinson’s Research
    • Extending Our Innovative Reach
      • Extending Our Innovative Reach
      • Team Up with Grifols Innovation and New Technologies
      • Scientific Awards and Programs
    • Connecting Knowledge - Our R&D Network
    • International Plasma Awareness Week
  • Sustainability
    • Sustainability
    • Social Commitment
      • Supporting Patients
      • Supporting Donors
      • Our People
      • Social Action
    • Environmental Responsibility
    • Ethical Leadership
    • Sustainability Reports & Corporate Policies
  • Products
  • Investors
    • Investors
    • Stock Information
      • Stock and share capital
      • Dividends
      • Major Holders and Treasury Stock
      • Agreements between Shareholders
      • Analyst Coverage
    • Financials
      • Financial Results
      • Annual Accounts
      • Fixed Income and Credit Ratings
      • Average Period of Payment to Suppliers
      • Key Figures
    • Press Releases
    • Presentations and Events
    • Agenda
    • Communications with CNMV and SEC
      • CNMV
      • SEC
      • Other Relevant Information
      • Inside Information
      • Significant events until 8 February 2020
    • Corporate Stewardship Reports
    • Corporate Governance
      • Board of Directors
      • General Shareholders’ Meeting
      • Annual Corporate Governance Report
      • Directors' Remuneration Report
      • Articles of Association
      • Corporate Policies
    • Mergers
    • Biotest: Voluntary Takeover Offer | Freiwilliges Übernahmeangebot (2021)
    • Biotest: Acquisition offer (delisting) / freiwilliges Erwerbsangebot (Delisting) (2025)
  • Careers
    • Careers
    • Why Grifols
      • Why Grifols
      • People & Culture
      • Our teams
    • Training and Development
    • Hiring Journey
    • Early Careers
  • Media
    • Media
    • Newsroom
    • Events
      • Events
      • H1 2026 Financial Results
      • General Shareholders' Meeting 2026
    • Media Contacts
    • Media Center
  • Suppliers
    • Suppliers
    • Join Grifols Supplier Network

Connect with us

'Grifols.com' logo 'Grifols.com' logo
About Us

About Us

  • Company
  • Sustainability
  • Innovation
  • Products
  • Investors
  • Careers
  • Media
Related Websites

Related Websites

  • Grifols Plasma
  • Grifols Diagnostics Solutions
  • Grifols Scientific Awards
  • Grifols Engineering
  • Grifols Egypt for Plasma Derivatives
  • Victor Grifols i Lucas Foundation
  • Probitas Foundation
  • J.A. Grifols Foundation
Legal & Help

Legal & Help

  • Privacy Notices
  • Cookies Policy
  • Cookies Settings
  • Terms of Use
  • Grifols Ethics Line
  • Contact
  • Glossary

Connect with us

© 2026 Grifols, S.A. All rights reserved worldwide.